Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Rilotumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Rilotumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Rilotumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Rilotumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Rilotumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Rilotumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Rilotumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Rilotumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Rilotumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Rilotumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Rilotumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Rilotumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Rilotumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rilotumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rilotumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Rilotumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Rilotumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Rilotumumab. |
| Equol | Equol may increase the thrombogenic activities of Rilotumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Rilotumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Rilotumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Rilotumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Rilotumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Rilotumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Rilotumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Rilotumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Rilotumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Rilotumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Rilotumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Rilotumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Rilotumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rilotumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Rilotumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilotumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Rilotumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilotumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rilotumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Rilotumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rilotumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Rilotumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilotumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Rilotumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rilotumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilotumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilotumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rilotumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilotumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilotumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Rilotumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Rilotumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilotumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilotumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rilotumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Rilotumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Rilotumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Rilotumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Rilotumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Rilotumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Rilotumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Rilotumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Rilotumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Rilotumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Rilotumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Rilotumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Rilotumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Rilotumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Rilotumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Rilotumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Rilotumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Rilotumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Rilotumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Rilotumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Rilotumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Rilotumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Rilotumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Rilotumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Rilotumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Rilotumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Rilotumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Rilotumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Rilotumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Rilotumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Rilotumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Rilotumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Rilotumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Rilotumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rilotumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Rilotumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Rilotumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Rilotumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Rilotumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Rilotumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Rilotumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Rilotumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Rilotumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Rilotumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Rilotumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Rilotumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Rilotumumab. |